Drugmaker Granules says it will tighten internal oversight following a warning from the US FDA. The company, one of the world’s biggest paracetamol makers and a key active pharmaceutical ingredients player, earns a large share of revenue from the United States—making compliance scrutiny especially consequential for future supply and sales.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
